Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Similar articles for PubMed (Select 21131577)

1.

Reduction in physician reimbursement and use of hormone therapy in prostate cancer.

Elliott SP, Jarosek SL, Wilt TJ, Virnig BA.

J Natl Cancer Inst. 2010 Dec 15;102(24):1826-34. doi: 10.1093/jnci/djq417. Epub 2010 Dec 3.

2.

Medicare reimbursement and prescribing hormone therapy for prostate cancer.

Keating NL.

J Natl Cancer Inst. 2010 Dec 15;102(24):1814-5. doi: 10.1093/jnci/djq467. Epub 2010 Dec 3. No abstract available.

3.

Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study.

Holmes JA, Wang AZ, Hoffman KE, Hendrix LH, Rosenman JG, Carpenter WR, Godley PA, Chen RC.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):88-94. doi: 10.1016/j.ijrobp.2011.10.076. Epub 2012 Jan 31.

PMID:
22300560
4.

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1439-44. doi: 10.1016/j.ijrobp.2009.03.034. Epub 2009 Jun 18.

PMID:
19540066
5.

Survival following primary androgen deprivation therapy among men with localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA. 2008 Jul 9;300(2):173-81. doi: 10.1001/jama.300.2.173. Erratum in: JAMA. 2009 Jan 7;301(1):38.

6.

Factors associated with reduction in use of neoadjuvant androgen suppression therapy before radical prostatectomy.

O'Shaughnessy MJ, Jarosek SL, Virnig BA, Konety BR, Elliott SP.

Urology. 2013 Apr;81(4):745-51. doi: 10.1016/j.urology.2012.12.044.

PMID:
23465162
7.

Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.

Underwood W 3rd, Jackson J, Wei JT, Dunn R, Baker E, Demonner S, Wood DP.

Cancer. 2005 Feb 1;103(3):538-45.

8.

Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture.

Elliott SP, Jarosek SL, Alanee SR, Konety BR, Dusenbery KE, Virnig BA.

Cancer. 2011 Oct 1;117(19):4557-65. doi: 10.1002/cncr.25994. Epub 2011 Mar 16.

9.

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA Intern Med. 2014 Sep;174(9):1460-7. doi: 10.1001/jamainternmed.2014.3028.

PMID:
25023796
10.

Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.

Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1046-52. doi: 10.1016/j.ijrobp.2009.06.038. Epub 2009 Oct 26.

PMID:
19864082
12.

[Combined treatment of metastatic hormone-resistant prostate cancer].

Kaprin AD, Gafanov RA, Al'bitskiń≠ IA, Fastovets SV.

Vopr Onkol. 2009;55(4):477-9. Russian. No abstract available.

PMID:
19947375
13.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

14.

Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.

Chang SL, Liao JC, Shinghal R.

J Urol. 2009 Jul;182(1):255-60; discussion 261. doi: 10.1016/j.juro.2009.02.141. Epub 2009 May 17.

PMID:
19450844
16.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
17.

Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.

Kuykendal AR, Hendrix LH, Salloum RG, Godley PA, Chen RC.

Ann Oncol. 2013 May;24(5):1338-43. doi: 10.1093/annonc/mds618. Epub 2012 Dec 30.

18.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
19.

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.

BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.

PMID:
22540922
20.

Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.

Quek RG, Master VA, Portier KM, Ward KC, Lin CC, Virgo KS, Lipscomb J.

Urol Oncol. 2014 Aug;32(6):748-60. doi: 10.1016/j.urolonc.2014.02.017. Epub 2014 May 16.

PMID:
24840868
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk